.alpha..sub.1C specific compounds to treat benign prostatic hyperplasia

US5990128A · kind A · utility

Assignee

• Synaptic Pharmaceutical Corporation · US

Inventors

• Charles Gluchowski · Mission Viejo, US
• Carlos Forray · Paramus, US
• George Chiu · Bound Brook, US
• Theresa Branchek · Teaneck, US
• John Wetzel · Elmwood Park, US
• Paul R. Hartig · Mahwah, US

Key dates

• Filing date: Nov 22, 1996
• Grant date: Nov 23, 1999
• Expiry date: Nov 22, 2016

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2602/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor; and (b) binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than 100-fold lower than the binding affinity with which the .alpha..sub.1C antagonist binds to such .alpha..sub.1C adrenergic receptor. The invention further provides a method of inhibiting contraction of a prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic recept…